Clinical Trial Update: Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial investigating long-acting exenatide for cognitive decline in dysglycemic patients; status and results are not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Dysglycemia

Drugs mentioned

• Long-acting exenatide (exenatide long-acting formulation)

Snippet

Sponsor: Azienda Ospedaliero-Universitaria di Parma | Conditions: Dysglycemia, Cognitive Deficit | Phase 3 | Status: UNKNOWN